商品名:利拉利汀
别 名:8-[(3R)-3-氨基-1-哌啶基]-7-(2-丁炔基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基]-1H-嘌呤-2,6-二酮;利拉利汀;利拉利;利拉利汀;linagliptin;8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione;(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione;1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-;Bi 1356;Ondero;8-[(3R)-3-aMinopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-Methyl-1-[(4-Methylquinazolin-2-yl)Methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione
英文名:Linagliptin
产 地:湖南
Cas号:668270-12-0
MDL:
Beilstein:
EINECS:
分子结构:
分子式:C25H28N8O2
分子量:472.5400
备注:
性状:类白色至黄色粉末。熔点 202 ºC,密度 1.39。
质量标准:含量98%以上
存储:密封保存。
用途:激素及调节内分泌;糖尿病原料药。
联合编号:
RISK:
Safety:
Hazard: